Sanofi fights back This represents Sanofi's first foray into the biosimilar diabetes market ... The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar ... Merilog to Sanofi-Aventis U.S ...

and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company ... and affordability of Insulin Aspart in the United States.